Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jun 2022 According to a Taiho Pharmaceutical media release, based on the data from this study, company has obtained manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for the oral heat shock protein (HSP) 90 inhibitor Jeselhy Tablets 40 mg for the indication of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
07 Jun 2022 Status changed from not yet recruiting to completed, according to Results published in the Annals of Oncology.
07 Jun 2022 Results assessing efficacy and safety of pimitespib in advanced GIST were published in the Annals of Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com